Press Releases
Preclinical update – Debio-0512 therapeutic vaccine for the treatment of chronic and acute inflammatory conditions – Proof of concept in…
Debiopharm signs R&D and Commercialisation Agreement with Kirin for the development of Debio-0719 in Oncology
Debiopharm presents new data confirming anti-HCV activity of cyclophilin inhibitor for Debio-025
Debiopharm and Cambridge Antibody Technology enter into an exclusive agreement to develop and market SC-1 for gastric carcinomas
Debiopharm and EPFL honour Dr Eduard Batlle with the “Debiopharm Life Sciences Award”
The Japanese Cancer Association (JCA) and Debiopharm honour Professors Masanori Hatakeyama and Johji Inazawa with the 2006 JCA-Mauvernay Award
Debiopharm granted European Orphan Drugs Status for Debio-0513 (PTR-262) for Myasthenia Gravis